Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 7/20 | 0.54 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2835415 | 1.00 | FFAR2 (0.54) | FFAR2S1PR5KCNH2NR4A1NR4A2 | |
| SCHEMBL2837206 | 1.00 | FFAR2 (0.54) | FFAR2S1PR5KCNH2NR4A1NR4A2 | |
| SCHEMBL2713220 | 0.90 | KCNH2 (0.55) | FFAR2S1PR5KCNH2NR4A1NR4A2 | |
| SCHEMBL2712695 | 0.90 | KCNH2 (0.55) | FFAR2S1PR5KCNH2NR4A1NR4A2 | |
| SCHEMBL2714652 | 0.90 | KCNH2 (0.55) | FFAR2S1PR5KCNH2NR4A1NR4A2 | |
| SCHEMBL2832488 | 0.87 | FFAR2 (0.52) | FFAR2KCNH2NR4A2MAOB | |
| SCHEMBL841242 | 0.85 | FFAR2 (0.49) | FFAR2S1PR5KCNH2 | |
| SCHEMBL311160 | 0.85 | FFAR2 (0.49) | FFAR2S1PR5KCNH2 | |
| SCHEMBL13310682 | 0.85 | FFAR2 (0.49) | FFAR2S1PR5KCNH2MAOB | |
| SCHEMBL840904 | 0.85 | FFAR2 (0.49) | FFAR2S1PR5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324022-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| US-7803833-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-20080293753-A1 | Novel Compounds | Convergence Pharmaceuticals Limited (GB) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324022-A1 | NOVEL COMPOUNDS | CYP46A1, NPC1, CYP11B1 | FFAR2 1237/4885S1PR5 1971/4885KCNH2 3260/4885 |
| US-20080293753-A1 | Novel Compounds | CACNA1E, CACNA1A, SCN1B | FFAR2 1216/4885S1PR5 1143/4885KCNH2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.